In 2021, total size of the cardiac biomarkers market was USD 8,459.6 million and it will generate a revenue of USD 20,718.8 million by 2030, pushing at a growth rate of 10.5%.
 |
| To learn more about this report: https://bit.ly/3OHl2n4 |
Troponin had the major share of revenue of 35% in the recent past, and it will grow at a healthy rate in the years to come. It has a lot to do with the unexpected specificity, and capacity of their protein complex for supporting recognizing cardiac issues, including ACS, with accuracy.
Moreover, the increasing cases of myocardial infraction will boost the industry, as troponin is a prevalent tool for detecting this condition.
In addition to this, myocardial muscle creatine kinase will grow considerably, followed by troponin, in the years to come.
The industry is growing because of the increasing cases of cardiovascular diseases. As per the World Health Organization, about 18 million people die worldwide, which is 31% of all the global fatalities.
North America is the highest revenue contributor in the industry, with a revenue share of more than 35% in the past. This has a lot to do with the increasing use of biomarkers for precision medicine, different strategies for growth adopted by market players, and the increasing acceptance of biomarkers for the detection of cardiac ailments.
APAC will have the fastest growth at a rate of 11%. The reasons for this growth are developing healthcare infra, numerous government schemes for the healthcare sector, increasing prevalence of cardiac diseases etc.
It is because of the increasing incidence for the acute coronary syndrome, the demand for the cardiac biomarkers is on the rise globally.
